The use of an LHRH agonist, buserelin, in the long-term management of premenstrual syndromes.
Buserelin, an LHRH agonist, was given by nasal spray to 20 women with premenstrual syndrome. In 10 women benefits were such that they continued treatment for periods varying from 5 to 15 months. There were significant improvements in mood and physical symptoms, and side-effects such as hot flushes were mild. The remaining 10 women were all made worse by the spray and stopped it within 2 months. Ovulation was blocked in all women though six showed evidence of ovulation during the first treatment month, and two women later in treatment. Of the long-term group, six eventually became amenorrhoeic, and four continued to menstruate. There was a significant improvement in symptoms during treatment in the long-term group. Physical symptoms continued to be worse before any menstrual bleeding. Mood change lost its relationship to menstruation. The adverse effects in the short-term group were sometimes severe and it is necessary to identify the characteristics of the woman who are likely to show such reactions before recommending this treatment for more general use.
D000328:Adult; D000339:Affect / Q000187:drug effects; D001519:Behavior / Q000187:drug effects; D002064:Buserelin / Q000009:adverse effects / Q000627:therapeutic use*; D004967:Estrogens / Q000652:urine; D005260:Female; D006801:Humans; D008598:Menstruation / Q000187:drug effects; D010060:Ovulation / Q000187:drug effects; D011293:Premenstrual Syndrome / Q000188:drug therapy* / Q000523:psychology; D013997:Time Factors
D004967:Estrogens; D002064:Buserelin